Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose

World News: . []

SANTA MONICA Calif Feb 12 2018 GLOBE NEWSWIRE -- Opiant Pharmaceuticals Inc Opiant NASDAQOPNT a specialty pharmaceutical company developing pharmacological treatments for addictions today announced positive data from a Phase I cl inical ...

More news and information about Opiant Pharmaceuticals, Inc.

Published By:

Globe Newswire: 13:00 GMT Monday 12th February 2018

Published: .

Search for other references to "opiant" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us